PURPOSE: Gastrointestinal cancer (GI) incidence increases with each decade of life and is the leading cause of death in patients aged >70 years. Nevertheless, elderly patients are often excluded or underrepresented in clinical trials. We performed a review of current recommendations in the management of GI elderly cancer patients. METHODS: A comprehensive literature review was performed analyzing data about several meta-analysis and studies regarding chemotherapeutic regimens in elderly patients with colorectal and gastroesophageal cancers. RESULTS: Most of the studies demonstrated that the elderly experience the same advantages and toxicities from chemotherapy as younger individuals despite the fact that the data reviewed in this article provide evidence that elderly with GI cancers are underrepresented in clinical trials and few trials are conducted addressing the different risks and aims in older population. Each individual should be assessed for an appropriate regimen of treatment in the adjuvant or metastatic gastrointestinal cancer setting, and the decision of how to treat elderly must incorporate goals and preferences of the patient after a careful discussion of risks and benefits. CONCLUSION: Chronological age alone is not a sufficient factor to withhold curative/palliative treatment from an elderly GI cancer patient, and cofactors regarding their functional, social, and mental status have to be considered. For this purpose, several tools exist that may be utilized, such as geriatric assessment scores, comorbidity indices, frailty indices, scores for predicting toxicity from chemotherapy, and prognostic indices for survival.
PURPOSE:Gastrointestinal cancer (GI) incidence increases with each decade of life and is the leading cause of death in patients aged >70 years. Nevertheless, elderly patients are often excluded or underrepresented in clinical trials. We performed a review of current recommendations in the management of GI elderly cancerpatients. METHODS: A comprehensive literature review was performed analyzing data about several meta-analysis and studies regarding chemotherapeutic regimens in elderly patients with colorectal and gastroesophageal cancers. RESULTS: Most of the studies demonstrated that the elderly experience the same advantages and toxicities from chemotherapy as younger individuals despite the fact that the data reviewed in this article provide evidence that elderly with GI cancers are underrepresented in clinical trials and few trials are conducted addressing the different risks and aims in older population. Each individual should be assessed for an appropriate regimen of treatment in the adjuvant or metastatic gastrointestinal cancer setting, and the decision of how to treat elderly must incorporate goals and preferences of the patient after a careful discussion of risks and benefits. CONCLUSION: Chronological age alone is not a sufficient factor to withhold curative/palliative treatment from an elderly GI cancerpatient, and cofactors regarding their functional, social, and mental status have to be considered. For this purpose, several tools exist that may be utilized, such as geriatric assessment scores, comorbidity indices, frailty indices, scores for predicting toxicity from chemotherapy, and prognostic indices for survival.
Authors: Vijaya Sundararajan; Nandita Mitra; Judith S Jacobson; Victor R Grann; Daniel F Heitjan; Alfred I Neugut Journal: Ann Intern Med Date: 2002-03-05 Impact factor: 25.391
Authors: Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani Journal: J Clin Oncol Date: 2006-11-01 Impact factor: 44.544
Authors: M Bouchahda; T Macarulla; J P Spano; J B Bachet; G Lledo; T Andre; B Landi; J Tabernero; A Karaboué; J Domont; F Levi; P Rougier Journal: Crit Rev Oncol Hematol Date: 2008-04-08 Impact factor: 6.312
Authors: Matthew T Seymour; Lindsay C Thompson; Harpreet S Wasan; Gary Middleton; Alison E Brewster; Stephen F Shepherd; M Sinead O'Mahony; Timothy S Maughan; Mahesh Parmar; Ruth E Langley Journal: Lancet Date: 2011-05-11 Impact factor: 79.321
Authors: Stefan Munker; Michael Gerken; Petra Fest; Claudia Ott; Elisabeth Schnoy; Stefan Fichtner-Feigl; Philipp Wiggermann; Martin Vogelhuber; Wolfgang Herr; Christian Stroszczynski; Hans Jürgen Schlitt; Matthias Evert; Michael Reng; Monika Klinkhammer-Schalke; Andreas Teufel Journal: BMC Cancer Date: 2018-04-23 Impact factor: 4.430
Authors: Jeroen L A van Vugt; Stef Levolger; Arvind Gharbharan; Marcel Koek; Wiro J Niessen; Jacobus W A Burger; Sten P Willemsen; Ron W F de Bruin; Jan N M IJzermans Journal: J Cachexia Sarcopenia Muscle Date: 2016-11-22 Impact factor: 12.910
Authors: Troels G Dolin; Marta Mikkelsen; Henrik L Jakobsen; Tyge Nordentoft; Trine S Pedersen; Anders Vinther; Bo Zerahn; Kirsten K Vistisen; Charlotte Suetta; Dorte Nielsen; Julia S Johansen; Cecilia M Lund Journal: BMC Geriatr Date: 2021-01-30 Impact factor: 3.921